Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present LivaNova PLC (NASDAQ: LIVN).

Full DD Report for LIVN

You must become a subscriber to view this report.


Recent News from (NASDAQ: LIVN)

Abbott's MITRA-FR Potentially Not As Negative As It Appears For Upcoming COAPT Results
Strong Broad-Based Growth; Recent Discussion Focused on MitraClip Abbott Laboratories ( ABT ) is a diversified healthcare conglomerate with revenue coming from Medical Devices, Nutrition, Diagnostics, and Established Pharma (generic pharmaceuticals). The stock has performed well as its segme...
Source: SeekingAlpha
Date: September, 13 2018 16:47
LivaNova Welcomes NICE Interventional Procedures Guidance on Sutureless Aortic Valve Replacement
Announcement comes as Company completes enrollment in PERSIST-AVR Trial for Perceval sutureless aortic valve LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, welcomes the recently updated interventional procedures guidance for sutureless aortic valve replacemen...
Source: Business Wire
Date: September, 10 2018 09:00
LivaNova VNS Therapy System for Drug-Resistant Epilepsy Could Save $77,000 Per Patient Over Five Years
Analysis finds overall cost savings far exceed system-related costs LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that a new cost analysis found the Company’s Vagus Nerve Stimulation Therapy ® (VNS Therapy) System results in lowe...
Source: Business Wire
Date: September, 04 2018 09:00
Tracking George Soros's Portfolio - Q2 2018 Update
This article is part of a series that provides an ongoing analysis of the changes made to George Soros's 13F stock portfolio on a quarterly basis. It is based on George Soros's regulatory 13F Form filed on 08/16/2018. Please visit our Tracking Soros Fund Management Holdings article for an ...
Source: SeekingAlpha
Date: September, 02 2018 14:22
LivaNova Launches Global Clinical Registry to Assess VNS Therapy Treatment for Drug-Resistant Epilepsy Patients
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the first implanted patient and official launch of a global registry to evaluate the use of LivaNova’s Vagus Nerve Stimulation Therapy ® (VNS Therapy) System for patients with drug-resistant...
Source: Business Wire
Date: August, 23 2018 09:28

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-14131.27126.01131.27124.93582,445
2018-02-2688.2087.9988.9587.76401,019
2018-02-2386.0187.8788.5684.96248,546
2018-02-2287.9985.9187.9985.50370,573
2018-02-2184.8786.0487.74584.47389,108

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1138,212102,43837.3026Short
2018-12-1036,90780,06046.0992Short
2018-12-0794,674112,33384.2798Short
2018-12-0654,835124,18844.1548Short
2018-12-0439,76293,91642.3378Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on LIVN.


About LivaNova PLC (NASDAQ: LIVN)

Logo for LivaNova PLC (NASDAQ: LIVN)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $4,031,301,397 - 05/17/2018
  • Issue and Outstanding: 48,435,677 - 04/26/2018

 


Recent Filings from (NASDAQ: LIVN)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 31 2018
Specialized Disclosure Report
Filing Type: SDFiling Source: edgar
Filing Date: May, 31 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: May, 31 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 25 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018

 

 


Daily Technical Chart for (NASDAQ: LIVN)

Daily Technical Chart for (NASDAQ: LIVN)


Stay tuned for daily updates and more on (NASDAQ: LIVN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: LIVN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in LIVN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of LIVN and does not buy, sell, or trade any shares of LIVN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/